Eclipse Regenesis is developing the Eclipse XL1, the first tissue regeneration therapy specifically designed for patients with Short Bowel Syndrome (SBS), a condition that severely limits nutrient absorption due to intestinal resection. This therapy aims to restore the body's natural tissue regeneration capabilities, reducing reliance on Total Parenteral Nutrition and improving overall nutrient uptake.
Funding
$210K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
CFFounders
Product
Problem
Short Bowel Syndrome (SBS) patients often struggle to absorb sufficient nutrients due to intestinal resection, leading to reliance on life-sustaining solutions with significant drawbacks. Current treatments like Total Parenteral Nutrition (TPN) can cause frequent hospitalizations and liver disease, while drug therapies offer minimal absorption improvement, and surgery carries risks of infection, rejection, and death. A restorative solution is needed to improve nutrient absorption and reduce dependence on these burdensome interventions.
Solution
Eclipse Regenesis is developing the Eclipse XL1, a tissue regeneration therapy designed to restore the body's natural ability to regenerate intestinal tissue in Short Bowel Syndrome (SBS) patients. This approach aims to improve nutrient absorption, thereby reducing or eliminating the need for Total Parenteral Nutrition (TPN) and other supportive therapies. By addressing the underlying cause of malabsorption, the Eclipse XL1 offers a potential restorative solution for patients with SBS, improving their overall quality of life and reducing the complications associated with current treatments.
Target Audience
The primary target audience includes patients with Short Bowel Syndrome (SBS) who require improved nutrient absorption and a reduction in their dependence on Total Parenteral Nutrition (TPN) or other therapies.
Features
- Tissue regeneration therapy specifically designed for Short Bowel Syndrome (SBS)
- Aims to restore natural intestinal tissue regeneration capabilities
- Designed to improve nutrient absorption
- Intended to reduce or eliminate reliance on Total Parenteral Nutrition (TPN)